Home › Funds › Rubric Capital Management LP › SPRY

Rubric Capital Management LP position in SPRY

ARS PHARMACEUTICALS INC · Health Care

Rubric Capital Management LP reported holding 8,540,861 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$68.4M, representing 0.63% of its reported portfolio and ranking #45 among its reported holdings. Rubric Capital Management LP has disclosed SPRY holdings in 10 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)8.54M sh
Reported value held$68.41M
Portfolio Weight0.63%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Rubric Capital Management LP's SPRY position evolved

Rubric Capital Management LP first disclosed a stake in SPRY in Q3 2023 at 639,203 shares (US$2.4M). The position peaked in Q4 2025 at 6,200,000 shares, worth US$72.2M. Across 10 filings, Rubric Capital Management LP increased the stake 5 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 8,540,861 shares valued at US$68.4M — an increase of 540,861 shares quarter over quarter.. Notable position changes include a 248% increase in Q3 2025 (shares rose 16% over the following quarter), a 38% increase in Q4 2025 (shares fell 31% over the following quarter), a 29% increase in Q1 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 639.20K $2.42M New
Q4 2023 639.20K $3.50M Hold
Q1 2024 639.20K $6.53M Hold
Q2 2024 639.20K $5.44M Hold
Q1 2025 1.03M $12.95M New
Q2 2025 1.29M $22.60M Add
Q3 2025 4.50M $45.23M Add
Q4 2025 6.20M $72.23M Add
Q1 2026 8.00M $64.24M Add
Q2 2026 8.54M $68.41M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SPRY and 13F data

SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 24 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), ORBIMED ADVISORS LLC (US$66.4M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$60.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SPRY

All SPRY fund holders →

FAQ

How long has Rubric Capital Management LP held SPRY?

Rubric Capital Management LP has disclosed SPRY holdings in 10 of the last 12 reported quarters, going back to Q3 2023.

What is Rubric Capital Management LP's current position in SPRY?

As of Q2 2026, Rubric Capital Management LP holds 8.54M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $68.41M, representing 0.63% of its reported portfolio and ranking #45.

Has Rubric Capital Management LP been buying or selling SPRY?

In the latest 13F filing (Q2 2026), Rubric Capital Management LP increased its position in SPRY. The position peaked in Q4 2025 at 6.20M shares.

Which other funds hold SPRY?

Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.